PL1694360T3 - Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia chorób autoimmunologicznych i zapalnych oraz odrzucenia przeszczepu narządów - Google Patents

Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia chorób autoimmunologicznych i zapalnych oraz odrzucenia przeszczepu narządów

Info

Publication number: PL1694360T3
Authority: PL; Poland
Prior art keywords: antagonist anti; dosing regimen; autoimmune; antibodies; treatment
Prior art date: 2003-11-04

Application number

PL04810420T

Other languages

English (en)

Inventor

Li Long

Mohammad Luqman

Asha Yabannavar

Isabel Zaror

Original Assignee

Novartis Vaccines & Diagnostics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-04

Filing date

2004-11-04

Publication date

2011-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34577667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1694360(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-04 Application filed by Novartis Vaccines & Diagnostics Inc filed Critical Novartis Vaccines & Diagnostics Inc

2011-04-29 Publication of PL1694360T3 publication Critical patent/PL1694360T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Neurology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)

PL04810420T 2003-11-04 2004-11-04 Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia chorób autoimmunologicznych i zapalnych oraz odrzucenia przeszczepu narządów PL1694360T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US51733703P	2003-11-04	2003-11-04
US52557903P	2003-11-26	2003-11-26
US56571004P	2004-04-27	2004-04-27
EP04810420A EP1694360B1 (en)	2003-11-04	2004-11-04	Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
PCT/US2004/036957 WO2005044306A2 (en)	2003-11-04	2004-11-04	Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection

Publications (1)

Publication Number	Publication Date
PL1694360T3 true PL1694360T3 (pl)	2011-04-29

Family

ID=34577667

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL09075395T PL2149585T3 (pl)	2003-11-04	2004-11-04	Zastosowanie antagonistycznych przeciwciał monoklonalnych anty-CD40
PL04810510T PL1682180T3 (pl)	2003-11-04	2004-11-04	Antagonistyczne przeciwciała monoklonalne anty-CD40 i sposoby ich zastosowania
PL04810421T PL1682178T3 (pl)	2003-11-04	2004-11-04	Sposoby terapii nowotworów wykazujących ekspresje antygenu CD40
PL04810420T PL1694360T3 (pl)	2003-11-04	2004-11-04	Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia chorób autoimmunologicznych i zapalnych oraz odrzucenia przeszczepu narządów

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PL09075395T PL2149585T3 (pl)	2003-11-04	2004-11-04	Zastosowanie antagonistycznych przeciwciał monoklonalnych anty-CD40
PL04810510T PL1682180T3 (pl)	2003-11-04	2004-11-04	Antagonistyczne przeciwciała monoklonalne anty-CD40 i sposoby ich zastosowania
PL04810421T PL1682178T3 (pl)	2003-11-04	2004-11-04	Sposoby terapii nowotworów wykazujących ekspresje antygenu CD40

Country Status (22)

Country	Link
EP (6)	EP1694360B1 (pl)
JP (6)	JP4765039B2 (pl)
KR (2)	KR101125127B1 (pl)
CN (2)	CN1938045B (pl)
AT (3)	ATE476448T1 (pl)
AU (3)	AU2004287482B2 (pl)
CA (3)	CA2544949C (pl)
CY (3)	CY1110231T1 (pl)
DE (3)	DE602004028505D1 (pl)
DK (4)	DK1694360T3 (pl)
EC (2)	ECSP066607A (pl)
ES (3)	ES2333971T3 (pl)
HR (2)	HRP20100066T1 (pl)
IL (1)	IL175225A (pl)
MA (1)	MA28331A1 (pl)
PL (4)	PL2149585T3 (pl)
PT (4)	PT1682180E (pl)
RS (2)	RS51230B (pl)
SG (1)	SG148143A1 (pl)
SI (3)	SI1682178T1 (pl)
WO (3)	WO2005044854A2 (pl)
ZA (1)	ZA200604419B (pl)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP2236172A1 (en) *	2003-11-04	2010-10-06	Novartis Vaccines and Diagnostics, Inc.	Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
SI1682178T1 (sl) *	2003-11-04	2010-11-30	Novartis Vaccines & Diagnostic	Postopki za terapijo raka ob eksprimiranju CD antigena
US8277810B2 (en)	2003-11-04	2012-10-02	Novartis Vaccines & Diagnostics, Inc.	Antagonist anti-CD40 antibodies
US20050281815A1 (en) *	2004-02-26	2005-12-22	Dani Eshel	CD40 splice variants and their uses
JP5421590B2 (ja) *	2005-05-18	2014-02-19	ノバルティスアーゲー	自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
CA2608751A1 (en) *	2005-05-18	2006-11-23	Novartis Ag	Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
CN101217979A (zh)	2005-06-14	2008-07-09	安姆根有限公司	自缓冲蛋白制剂
BRPI0618217A2 (pt) *	2005-11-01	2011-08-23	Novartis Ag	usos de anticorpos anti-cd40
JP2009517339A (ja) *	2005-11-01	2009-04-30	ノバルティスアーゲー	抗ｃｄ４０抗体の使用
PL1976877T5 (pl)	2005-11-30	2017-09-29	Abbvie Inc	Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
CN117903302A (zh)	2005-11-30	2024-04-19	Abbvie 公司	抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
EP3327117A1 (en)	2005-12-09	2018-05-30	Academisch Medisch Centrum bij de Universiteit van Amsterdam	Means and methods for influencing the stability of antibody producing cells
WO2007067032A1 (en)	2005-12-09	2007-06-14	Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam	Means and methods for influencing the stability of cells
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
GEP20125628B (en) *	2006-04-21	2012-09-10	Novartis Ag	Pharmaceutical compositions containing antagonist anti-cd40 antibody
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AU2007338791B2 (en) *	2006-12-21	2014-03-13	Amgen Inc	Stable buffered formulations containing polypeptides
EP2486928A1 (en)	2007-02-27	2012-08-15	Abbott GmbH & Co. KG	Method for the treatment of amyloidoses
EP2170268A2 (en)	2007-06-25	2010-04-07	Amgen, Inc.	Compositions of specific binding agents to hepatocyte growth factor
US9068230B2 (en)	2007-11-07	2015-06-30	Genentech, Inc.	Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
CA2705263A1 (en) *	2007-11-09	2009-05-14	Novartis Ag	Combination therapy with an antagonist anti-cd 40 antibody and cyclophosphamide, doxorubicin, vincristine and prednisone (chop) for treatment of b-cell malignancies
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2758523C (en)	2009-04-18	2019-03-12	Genentech, Inc.	Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
CA2768207C (en)	2009-07-15	2019-12-03	Aimm Therapeutics B.V.	Means and methods for producing high affinity antibodies
MX360403B (es)	2010-04-15	2018-10-31	Abbvie Inc	Proteinas de union a amiloide beta.
EP2603524A1 (en)	2010-08-14	2013-06-19	AbbVie Inc.	Amyloid-beta binding proteins
NZ610592A (en)	2010-11-04	2015-03-27	Boehringer Ingelheim Int	Anti-il-23 antibodies
AR083847A1 (es) *	2010-11-15	2013-03-27	Novartis Ag	Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
AU2016201742B2 (en) *	2010-11-15	2017-11-02	Novartis Ag	Silent Fc variants of anti-CD40 antibodies
WO2012075111A1 (en)	2010-11-30	2012-06-07	Novartis Ag	Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
PT2646466T (pt)	2010-12-02	2017-06-07	Aimm Therapeutics Bv	Meios e métodos para produzir anticorpos de alta afinidade
ES2734076T3 (es) *	2011-02-17	2019-12-04	Kyowa Hakko Kirin Co Ltd	Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada
US9713636B2 (en) *	2011-02-28	2017-07-25	Napajen Pharma, Inc.	Nucleic acid/polysaccharide complex
PL3556774T3 (pl)	2011-03-11	2024-07-01	Beth Israel Deaconess Medical Center Inc.	Przeciwciała anty-cd40 i ich zastosowania
MX354243B (es) *	2011-04-21	2018-02-20	Bristol Myers Squibb Co	Polipeptidos anticuerpos que antagonizan cd40.
US20140302021A1 (en)	2011-10-25	2014-10-09	Onclave Therapeutics Limited	Antibody formulations and methods
CA2855864A1 (en) *	2011-11-17	2013-05-23	Gundram Jung	Bi-specific antibodies for treating b-cell mediated autoimmune diseases or auto-reactive b-cells
JP6293120B2 (ja) *	2012-05-03	2018-03-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	抗ＩＬ−２３ｐ１９抗体
US20140004131A1 (en)	2012-05-04	2014-01-02	Novartis Ag	Antibody formulation
CN109265552A (zh) *	2012-10-30	2019-01-25	埃派斯进有限公司	抗-cd40抗体及其使用方法
KR102168562B1 (ko)	2012-11-19	2020-10-22	발리오팜 아게	Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
WO2014200349A1 (en) *	2013-06-13	2014-12-18	Fast Forward Pharmaceutical B.V.	Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
EP3099709B1 (en)	2014-01-31	2019-12-25	AIMM Therapeutics B.V.	Means and methods for producing stable antibodies
US10435475B2 (en)	2014-03-07	2019-10-08	Bristol-Myers Squibb Company	Method of using antibody polypeptides that antagonize CD40 to treat IBD
CN108025068A (zh) *	2014-03-12	2018-05-11	耶达研究与开发有限公司	降低系统性调节性t细胞水平或活性来治疗cns的疾病和损伤
US10618963B2 (en)	2014-03-12	2020-04-14	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
RU2690670C2 (ru)	2014-03-12	2019-06-05	Ида Рисерч Энд Дивелопмент Ко., Лтд	Снижение уровней или активности системных регуляторных т-клеток для лечения заболевания или повреждения цнс
US10519237B2 (en)	2014-03-12	2019-12-31	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
AU2015231180B2 (en) *	2014-03-19	2017-06-15	Bristol-Myers Squibb Company	Methods of treating transplant rejection using a domain antibody directed against CD40L
EP3708679A1 (en)	2014-07-24	2020-09-16	Boehringer Ingelheim International GmbH	Biomarkers useful in the treatment of il-23a related diseases
JP2017525370A (ja)	2014-08-21	2017-09-07	ザジェネラルホスピタルコーポレイション	腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
AP2017009776A0 (en)	2014-09-03	2017-02-28	Boehringer Ingelheim Int	Compound targeting il-23a and tnf-alpha and uses thereof
KR102656470B1 (ko)	2014-12-10	2024-04-09	리전츠 오브 더 유니버스티 오브 미네소타	질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
SG11201705728RA (en)	2015-02-04	2017-08-30	Boehringer Ingelheim Int	Methods of treating inflammatory diseases
CR20170592A (es)	2015-05-29	2018-02-13	Abbvie Inc	Anticuerpos anti-cd40 y sus usos
DK4209499T3 (da)	2015-08-13	2024-11-11	Amgen Inc	Ladet dybdefiltrering af antigenbindende proteiner
KR20250007054A (ko)	2015-09-04	2025-01-13	프리마토프 테라퓨틱스 인크.	인간화 항-cd40 항체 및 그의 용도
US10544229B2 (en) *	2015-09-30	2020-01-28	Janssen Biotech, Inc.	Agonistic antibodies specifically binding CD40 and methods of use
KR102414558B1 (ko)	2016-04-18	2022-06-29	셀덱스 쎄라퓨틱스, 인크.	인간 cd40에 결합하는 효능성 항체 및 이의 용도
KR102531889B1 (ko)	2016-06-20	2023-05-17	키맵 리미티드	항-pd-l1 및 il-2 사이토카인
BR112019000512A2 (pt)	2016-07-14	2019-04-24	Genmab A/S	anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
CN111344304B (zh) *	2017-06-01	2023-09-01	Pb免疫治疗公司	新型抗cd40抗体及其用途
KR20200012920A (ko) *	2017-06-01	2020-02-05	지앙수 헨그루이 메디슨 컴퍼니 리미티드	항-cd40 항체, 이의 항원 결합 단편 및 이의 의학적 용도
CA3082033A1 (en)	2017-08-24	2019-02-28	Novo Nordisk A\S	Glp-1 compositions and uses thereof
US11530259B2 (en) *	2018-01-29	2022-12-20	The Regents Of The University Of California	Therapies and methods to treat TLR2-mediated diseases and disorders
AU2019217207A1 (en) *	2018-02-12	2020-08-27	Diabetes-Free, Inc.	Improved antagonistic anti-human CD40 monoclonal antibodies
WO2019241730A2 (en)	2018-06-15	2019-12-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
WO2020102454A1 (en)	2018-11-13	2020-05-22	Regents Of The University Of Minnesota	Cd40 targeted peptides and uses thereof
AR117091A1 (es) *	2018-11-19	2021-07-07	Bristol Myers Squibb Co	Anticuerpos monoclonales antagonistas contra cd40 y sus usos
WO2020227159A2 (en)	2019-05-03	2020-11-12	Flagship Pioneering Innovations V, Inc.	Methods of modulating immune activity
JP2023509359A (ja)	2019-12-17	2023-03-08	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	鉄依存性細胞分解の誘導物質との併用抗癌療法
PE20221575A1 (es)	2020-02-18	2022-10-06	Novo Nordisk As	Formulaciones farmaceuticas
US20230355804A1 (en)	2020-06-29	2023-11-09	Flagship Pioneering Innovations V, Inc.	Viruses engineered to promote thanotransmission and their use in treating cancer
CN111763259B (zh) *	2020-09-03	2020-12-15	北京百奥赛图基因生物技术有限公司	抗cd40抗体及其用途
JP2024506831A (ja)	2021-01-28	2024-02-15	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	サイトカイン放出症候群を治療するための組成物及び方法
WO2023284714A1 (zh) *	2021-07-14	2023-01-19	舒泰神（北京）生物制药股份有限公司	特异性识别cd40的抗体及其应用
US12234294B2 (en)	2021-11-05	2025-02-25	Kiniksa Pharmaceuticals, Gmbh	Pharmaceutical composition of a humanized anti-CD40 antibody
CN117229396A (zh) *	2022-06-06	2023-12-15	普米斯生物技术(珠海)有限公司	抗cd40抗体及其用途
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2025184603A2 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR901228A (fr)	1943-01-16	1945-07-20	Deutsche Edelstahlwerke Ag	Système d'aimant à entrefer annulaire
NL154600B (nl)	1971-02-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3766162A (en)	1971-08-24	1973-10-16	Hoffmann La Roche	Barbituric acid antigens and antibodies specific therefor
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4233402A (en)	1978-04-05	1980-11-11	Syva Company	Reagents and method employing channeling
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
JPS5896026A (ja)	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
CA1341562C (en)	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
EP0091539B2 (en)	1982-03-31	1996-11-27	Ajinomoto Co., Inc.	Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
BE893016R (fr)	1982-04-29	1982-08-16	Amatucci Aldo	Turbine a vent
EP0098110B1 (en)	1982-06-24	1989-10-18	NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD	Long-acting composition
US4992271A (en)	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
FI82266C (fi)	1982-10-19	1991-02-11	Cetus Corp	Foerfarande foer framstaellning av il-2 -mutein.
US5700913A (en)	1982-12-15	1997-12-23	Ajinomoto Co., Inc.	Unglycosylated human interleukin-2 polypeptides
JPS60500673A (ja)	1983-03-08	1985-05-09	コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン	抗原活性を有するアミノ酸配列
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
WO1985000817A1 (en)	1983-08-10	1985-02-28	Amgen	Microbial expression of interleukin ii
US4569790A (en)	1984-03-28	1986-02-11	Cetus Corporation	Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en)	1984-03-28	1986-08-05	Cetus Corporation	Pharmaceutical compositions of microbially produced interleukin-2
US4656132A (en)	1984-03-28	1987-04-07	Cetus Corporation	Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4530787A (en)	1984-03-28	1985-07-23	Cetus Corporation	Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en)	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
CA1340265C (en)	1985-01-18	1998-12-15	Kirston E. Koths	Oxidation resistant muteins
US4752585A (en)	1985-12-17	1988-06-21	Cetus Corporation	Oxidation-resistant muteins
US5981216A (en)	1985-04-01	1999-11-09	Alusuisse Holdings A.G.	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4748234A (en)	1985-06-26	1988-05-31	Cetus Corporation	Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4816440A (en)	1985-09-26	1989-03-28	Cetus Corporation	Stable formulation of biologically active proteins for parenteral injection
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4745180A (en)	1986-06-27	1988-05-17	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using heparin fragments
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4931544A (en)	1986-09-04	1990-06-05	Cetus Corporation	Succinylated interleukin-2 for pharmaceutical compositions
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
CA1292686C (en)	1986-10-27	1991-12-03	Ze'ev Shaked	Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en)	1986-10-27	1992-01-14	Ze'ev Shaked	Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4894226A (en)	1986-11-14	1990-01-16	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
US4931543A (en)	1987-05-11	1990-06-05	Cetus Corporation	Process for recovering microbially produced interleukin-2
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5879936A (en)	1988-04-18	1999-03-09	Aluguisse Holding A.G.	Recombinant DNA methods, vectors and host cells
US5078997A (en)	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
WO1991004282A1 (fr)	1989-09-21	1991-04-04	Idemitsu Kosan Co., Ltd.	Polymere et copolymere d'arylstyrene et procede de preparation de tels polymeres
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
US5891693A (en)	1990-01-25	1999-04-06	Alusuisse Holdings A.G.	Recombinant DNA methods vectors and host cells
IE66205B1 (en)	1990-06-14	1995-12-13	Paul A Bartlett	Polypeptide analogs
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022543D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Antibody production
US5756096A (en)	1991-07-25	1998-05-26	Idec Pharmaceuticals Corporation	Recombinant antibodies for human therapy
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
US5962406A (en)	1991-10-25	1999-10-05	Immunex Corporation	Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5874082A (en)	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
AU5670194A (en)	1992-11-20	1994-06-22	Enzon, Inc.	Linker for linked fusion polypeptides
DE614989T1 (de)	1993-02-17	1995-09-28	Morphosys Proteinoptimierung	Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5674492A (en)	1993-12-23	1997-10-07	Immunex Corporation	Method of preventing or treating disease characterized by neoplastic cells expressing CD40
JPH09510088A (ja)	1994-03-03	1997-10-14	アレクション・ファーマシューティカル・インク	最終補体インヒビター融合遺伝子およびタンパク質
US6091001A (en)	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US5830698A (en)	1997-03-14	1998-11-03	Idec Pharmaceuticals Corporation	Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
ES2258817T3 (es)	1997-05-21	2006-09-01	Biovation Limited	Metodo para la produccion de proteinas no inmunogenas.
EP0999853B1 (en)	1997-06-13	2003-01-02	Genentech, Inc.	Stabilized antibody formulation
CZ295805B6 (cs)	1997-06-20	2005-11-16	Biogen Idec Ma Inc.	Léčivý přípravek obsahující monoklonální protilátku anti-CD154 nebo její derivát pro léčení syndromu inhibice exogenního proteinu
US6051228A (en) *	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
DZ2788A1 (fr)	1998-05-15	2003-12-01	Bayer Ag	Agonistes et antagonistes selectifs à IL-2.
US6168785B1 (en)	1998-07-16	2001-01-02	Institut Pasteur	Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
DE69934967T2 (de)	1998-12-08	2007-12-06	Biovation Ltd.	Verfahren zur verminderung der immunogenität von proteinen
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US20020006901A1 (en)	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en)	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
US6566500B1 (en)	1999-03-30	2003-05-20	Board Of Regents, The University Of Texas System	Compositions and methods for modifying toxic effects of proteinaceous compounds
CA2369820A1 (en)	1999-04-16	2000-10-26	Frank Dicker	Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
WO2001024814A1 (en)	1999-10-04	2001-04-12	Chiron Corporation	Stabilized liquid polypeptide-containing pharmaceutical compositions
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
AU1590201A (en) *	1999-11-09	2001-06-06	Chiron Corporation	Compositions and methods for treating autoimmune diseases and transplant rejections
JP2003530839A (ja)	2000-04-12	2003-10-21	プリンシピアファーマスーティカルコーポレイション	アルブミン融合タンパク質
AU2001259215A1 (en) *	2000-04-28	2001-11-12	La Jolla Institute For Allergy And Immunology	Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) *	2000-04-28	2003-03-27	Force Walker R.	Isolation and characterization of highly active anti-CD40 antibody
CA2424296A1 (en) *	2000-10-02	2002-04-11	Chiron Corporation	Human anti-cd40 antibodies
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
EP1455812A4 (en) *	2001-11-26	2006-03-22	Chiron Corp	TREATMENT OF ANTI-CD40 MONOCLONAL ANTIBODY FOR THE TREATMENT OF MULTIPLE SCLEROSIS
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
EP2236172A1 (en) *	2003-11-04	2010-10-06	Novartis Vaccines and Diagnostics, Inc.	Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
SI1682177T1 (sl) *	2003-11-04	2010-12-31	Novartis Vaccines & Diagnostic	Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije
SI1682178T1 (sl) *	2003-11-04	2010-11-30	Novartis Vaccines & Diagnostic	Postopki za terapijo raka ob eksprimiranju CD antigena
DK1684805T3 (da) *	2003-11-04	2010-10-04	Novartis Vaccines & Diagnostic	Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
CA2544852A1 (en) *	2003-11-04	2005-05-19	Chiron Corporation	Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
JP6039343B2 (ja)	2012-10-04	2016-12-07	キヤノン株式会社	電子機器、電子機器の制御方法、プログラム、記憶媒体

2004
- 2004-11-04 SI SI200431514T patent/SI1682178T1/sl unknown
- 2004-11-04 PT PT04810510T patent/PT1682180E/pt unknown
- 2004-11-04 ES ES04810510T patent/ES2333971T3/es not_active Expired - Lifetime
- 2004-11-04 PT PT90753955T patent/PT2149585E/pt unknown
- 2004-11-04 PL PL09075395T patent/PL2149585T3/pl unknown
- 2004-11-04 AT AT04810420T patent/ATE476448T1/de active
- 2004-11-04 PT PT04810420T patent/PT1694360E/pt unknown
- 2004-11-04 DK DK04810420.2T patent/DK1694360T3/da active
- 2004-11-04 CN CN200480037489.4A patent/CN1938045B/zh not_active Expired - Lifetime
- 2004-11-04 DK DK04810421.0T patent/DK1682178T3/da active
- 2004-11-04 EP EP04810420A patent/EP1694360B1/en not_active Expired - Lifetime
- 2004-11-04 JP JP2006538514A patent/JP4765039B2/ja not_active Expired - Fee Related
- 2004-11-04 EP EP10007970A patent/EP2248830A1/en not_active Withdrawn
- 2004-11-04 DE DE602004028505T patent/DE602004028505D1/de not_active Expired - Lifetime
- 2004-11-04 AU AU2004287482A patent/AU2004287482B2/en not_active Ceased
- 2004-11-04 EP EP09075395.5A patent/EP2149585B1/en not_active Expired - Lifetime
- 2004-11-04 HR HR20100066T patent/HRP20100066T1/hr unknown
- 2004-11-04 CA CA2544949A patent/CA2544949C/en not_active Expired - Fee Related
- 2004-11-04 ZA ZA200604419A patent/ZA200604419B/xx unknown
- 2004-11-04 JP JP2006538513A patent/JP4746552B2/ja not_active Expired - Lifetime
- 2004-11-04 RS RSP-2010/0041A patent/RS51230B/sr unknown
- 2004-11-04 DE DE602004023961T patent/DE602004023961D1/de not_active Expired - Lifetime
- 2004-11-04 PL PL04810510T patent/PL1682180T3/pl unknown
- 2004-11-04 AT AT04810421T patent/ATE473016T1/de active
- 2004-11-04 WO PCT/US2004/037152 patent/WO2005044854A2/en not_active Ceased
- 2004-11-04 EP EP10006780A patent/EP2255828A1/en not_active Withdrawn
- 2004-11-04 EP EP04810421A patent/EP1682178B8/en not_active Expired - Lifetime
- 2004-11-04 PT PT04810421T patent/PT1682178E/pt unknown
- 2004-11-04 CA CA002544948A patent/CA2544948A1/en not_active Abandoned
- 2004-11-04 AT AT04810510T patent/ATE447412T1/de active
- 2004-11-04 DE DE602004028037T patent/DE602004028037D1/de not_active Expired - Lifetime
- 2004-11-04 PL PL04810421T patent/PL1682178T3/pl unknown
- 2004-11-04 SI SI200431525T patent/SI1694360T1/sl unknown
- 2004-11-04 DK DK04810510T patent/DK1682180T3/da active
- 2004-11-04 RS RS20130482A patent/RS53073B/sr unknown
- 2004-11-04 WO PCT/US2004/036957 patent/WO2005044306A2/en not_active Ceased
- 2004-11-04 SI SI200431280T patent/SI1682180T1/sl unknown
- 2004-11-04 ES ES04810421T patent/ES2346977T3/es not_active Expired - Lifetime
- 2004-11-04 AU AU2004287879A patent/AU2004287879C1/en not_active Ceased
- 2004-11-04 JP JP2006538540A patent/JP5019881B2/ja not_active Expired - Lifetime
- 2004-11-04 WO PCT/US2004/036958 patent/WO2005044294A2/en not_active Ceased
- 2004-11-04 DK DK09075395.5T patent/DK2149585T3/da active
- 2004-11-04 CA CA2544853A patent/CA2544853C/en not_active Expired - Fee Related
- 2004-11-04 EP EP04810510A patent/EP1682180B1/en not_active Expired - Lifetime
- 2004-11-04 KR KR1020067010894A patent/KR101125127B1/ko not_active Expired - Fee Related
- 2004-11-04 ES ES09075395T patent/ES2435410T3/es not_active Expired - Lifetime
- 2004-11-04 KR KR1020067010885A patent/KR101403910B1/ko not_active Expired - Fee Related
- 2004-11-04 SG SG200808017-8A patent/SG148143A1/en unknown
- 2004-11-04 CN CN2004800390435A patent/CN1905897B/zh not_active Expired - Lifetime
- 2004-11-04 PL PL04810420T patent/PL1694360T3/pl unknown
2006
- 2006-04-26 IL IL175225A patent/IL175225A/en not_active IP Right Cessation
- 2006-06-05 MA MA29078A patent/MA28331A1/fr unknown
- 2006-06-05 EC EC2006006607A patent/ECSP066607A/es unknown
2010
- 2010-01-15 CY CY20101100045T patent/CY1110231T1/el unknown
- 2010-09-28 CY CY20101100869T patent/CY1110803T1/el unknown
- 2010-10-18 CY CY20101100931T patent/CY1110839T1/el unknown
- 2010-12-13 JP JP2010277537A patent/JP2011072317A/ja not_active Withdrawn
2011
- 2011-02-18 JP JP2011033969A patent/JP2011126900A/ja not_active Withdrawn
- 2011-02-25 JP JP2011040922A patent/JP2011105769A/ja not_active Withdrawn
- 2011-04-05 AU AU2011201529A patent/AU2011201529B2/en not_active Ceased
2012
- 2012-03-05 EC ECSP12006607 patent/ECSP12006607A/es unknown
2013
- 2013-11-13 HR HRP20131085TT patent/HRP20131085T1/hr unknown

Also Published As

Publication number	Publication date
SG148143A1 (en)	2008-12-31
CN1938045A (zh)	2007-03-28
JP2008502309A (ja)	2008-01-31
ES2333971T3 (es)	2010-03-03
WO2005044294A3 (en)	2005-09-15
CA2544949A1 (en)	2005-05-19
KR101125127B1 (ko)	2012-03-16
PL1682180T3 (pl)	2010-04-30
JP4746552B2 (ja)	2011-08-10
PL1682178T3 (pl)	2010-12-31
JP2011072317A (ja)	2011-04-14
CY1110839T1 (el)	2015-06-10
EP1682180B1 (en)	2009-11-04
RS51230B (sr)	2010-12-31
RS53073B (sr)	2014-04-30
AU2011201529B2 (en)	2012-11-01
JP5019881B2 (ja)	2012-09-05
WO2005044854A2 (en)	2005-05-19
EP1682178B8 (en)	2010-09-01
PT1682180E (pt)	2010-02-10
SI1682178T1 (sl)	2010-11-30
WO2005044294A2 (en)	2005-05-19
CN1938045B (zh)	2014-03-26
DK2149585T3 (da)	2013-10-21
HK1139964A1 (en)	2010-09-30
CA2544948A1 (en)	2005-05-19
IL175225A (en)	2011-12-29
AU2004287482B2 (en)	2011-04-14
HK1094156A1 (en)	2007-03-23
MA28331A1 (fr)	2006-12-01
EP1694360A2 (en)	2006-08-30
SI1694360T1 (sl)	2010-12-31
PL2149585T3 (pl)	2014-01-31
AU2004287879A1 (en)	2005-05-19
AU2011201529A1 (en)	2011-04-28
CY1110231T1 (el)	2015-01-14
DK1682178T3 (da)	2010-10-04
ECSP12006607A (es)	2012-04-30
DK1694360T3 (da)	2010-10-18
DE602004028037D1 (de)	2010-08-19
ATE476448T1 (de)	2010-08-15
PT1694360E (pt)	2010-12-13
JP2007512243A (ja)	2007-05-17
DK1682180T3 (da)	2010-01-11
ECSP066607A (es)	2006-10-25
CN1905897A (zh)	2007-01-31
CA2544853A1 (en)	2005-05-19
ES2346977T3 (es)	2010-10-22
JP2011105769A (ja)	2011-06-02
CY1110803T1 (el)	2015-06-10
CA2544949C (en)	2014-02-25
CN1905897B (zh)	2012-09-05
IL175225A0 (en)	2006-09-05
EP1682180A2 (en)	2006-07-26
HRP20131085T1 (hr)	2013-12-20
ZA200604419B (en)	2008-06-25
EP2248830A1 (en)	2010-11-10
EP2255828A1 (en)	2010-12-01
AU2004287879B2 (en)	2011-01-06
DE602004023961D1 (de)	2009-12-17
WO2005044306A2 (en)	2005-05-19
HRP20100066T1 (hr)	2010-03-31
WO2005044306A3 (en)	2005-09-15
EP1682178A2 (en)	2006-07-26
JP4765039B2 (ja)	2011-09-07
KR20060111555A (ko)	2006-10-27
HK1095091A1 (en)	2007-04-27
EP1694360B1 (en)	2010-08-04
KR20060132602A (ko)	2006-12-21
JP2011126900A (ja)	2011-06-30
EP1682178B1 (en)	2010-07-07
PT1682178E (pt)	2010-10-21
ATE447412T1 (de)	2009-11-15
PT2149585E (pt)	2013-11-27
AU2004287879C1 (en)	2011-05-26
CA2544853C (en)	2014-05-20
ATE473016T1 (de)	2010-07-15
ES2435410T3 (es)	2013-12-19
SI1682180T1 (sl)	2010-03-31
DE602004028505D1 (de)	2010-09-16
EP2149585A1 (en)	2010-02-03
KR101403910B1 (ko)	2014-06-09
JP2007510666A (ja)	2007-04-26
EP2149585B1 (en)	2013-08-14
WO2005044854A3 (en)	2005-08-11
AU2004287482A1 (en)	2005-05-19
HK1095270A1 (en)	2007-05-04

Publication	Publication Date	Title
PL1694360T3 (pl)	2011-04-29	Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia chorób autoimmunologicznych i zapalnych oraz odrzucenia przeszczepu narządów
CY1112473T1 (el)	2015-12-09	Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
CY1110874T1 (el)	2015-06-10	Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας
CY1111011T1 (el)	2015-06-11	Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος
RU2014141362A (ru)	2016-05-10	Комбинированная терапия пролиферативных нарушений
ATE541860T1 (de)	2012-02-15	Humane antikörper gegen cd40 zur therapie von b- zell tumoren
EA200301097A1 (ru)	2004-02-26	Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды
JP2014510047A5 (pl)	2015-04-02
WO2003061571A3 (en)	2005-07-07	Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
Agus et al.	1986	The effects of daily cyclophosphamide administration on the development and extent of primary experimental interstitial nephritis in rats
CA2368676A1 (en)	2000-10-05	Sphingomyelin containing preparation
RU2013127115A (ru)	2014-12-27	Комбинированная терапия при в-клеточных лимфомах
CY1114654T1 (el)	2016-12-14	Anti-cd40 μονοκλωνικα αντισωματα ανταγωνιστες και μεθοδοι για την χρηση αυτων